Drugs Made In America Acquisition II (NASDAQ:DMII) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Drugs Made In America Acquisition II (NASDAQ:DMII) to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

Drugs Made In America Acquisition II Price Performance

Shares of NASDAQ DMII opened at $10.19 on Friday. The company’s fifty day moving average is $10.17 and its 200-day moving average is $10.10. Drugs Made In America Acquisition II has a twelve month low of $9.86 and a twelve month high of $10.33.

Drugs Made In America Acquisition II (NASDAQ:DMII) last released its quarterly earnings data on Friday, August 14th. The company reported $0.07 EPS for the quarter.

Institutional Investors Weigh In On Drugs Made In America Acquisition II

Large investors have recently made changes to their positions in the stock. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Drugs Made In America Acquisition II during the first quarter worth approximately $19,960,000. Kryger Capital LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the first quarter valued at approximately $3,088,000. Rivernorth Capital Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the first quarter valued at approximately $2,991,000. SkyView Investment Advisors LLC bought a new position in shares of Drugs Made In America Acquisition II during the 2nd quarter worth approximately $2,515,000. Finally, Sona Asset Management US LLC boosted its stake in shares of Drugs Made In America Acquisition II by 66.7% during the 1st quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock worth $4,985,000 after acquiring an additional 200,000 shares during the period.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ: DMII) is a special purpose acquisition company (SPAC). The company was established to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Its stated focus is on identifying a target in the pharmaceutical, biotechnology or related healthcare sectors, with an emphasis on companies involved in drug development, manufacturing or other activities connected with medicines produced in the United States.